Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevention of COVID-19 by mRNA-based vaccines within the general population of California
Kristin L. Andrejko, Jake M. Pry, Jennifer F. Myers, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann
Nature reviews. Immunology (2021) Vol. 21, Iss. 8, pp. 475-484
Open Access | Times Cited: 532
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
Hannah Chung, Siyi He, Sharifa Nasreen, et al.
BMJ (2021), pp. n1943-n1943
Open Access | Times Cited: 287
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Karin Bok, Sandra Sitar, Barney S. Graham, et al.
Immunity (2021) Vol. 54, Iss. 8, pp. 1636-1651
Open Access | Times Cited: 230
Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals
Stephen M. Kissler, Joseph R. Fauver, Christina Mack, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 114
Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2
Stephen M. Kissler, Joseph R. Fauver, Christina Mack, et al.
medRxiv (2021)
Open Access | Times Cited: 103
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 82
The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases
Michal Stein, Liat Ashkenazi‐Hoffnung, David Greenberg, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 81-81
Open Access | Times Cited: 38
Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
Otávio T. Ranzani, Matt D. T. Hitchings, Murilo Dorión, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 53
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study
Hannah Chung, Siyi He, Sharifa Nasreen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 50
Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study
Kristin L. Andrejko, Jennifer F. Myers, Nozomi Fukui, et al.
Vaccine (2023) Vol. 41, Iss. 10, pp. 1649-1656
Open Access | Times Cited: 19
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines Against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario, Canada
Hannah Chung, Siyi He, Sharifa Nasreen, et al.
SSRN Electronic Journal (2021)
Open Access | Times Cited: 31
Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 30
Willingness and uptake of the COVID-19 testing and vaccination in urban China during the low-risk period: a cross-sectional study
Suhang Song, Shujie Zang, Liubing Gong, et al.
BMC Public Health (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
Lia Reynolds, Cate Dewey, Ghaid Asfour, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 11
Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following High-Risk Exposure
Kristin L. Andrejko, Jake M. Pry, Jennifer F. Myers, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e276-e288
Open Access | Times Cited: 24
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines
Joanna Szczepanek, Monika Skorupa, Agnieszka Goroncy, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 99-99
Open Access | Times Cited: 16
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 22
Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations
Jennifer R. Head, Kristin L. Andrejko, Justin V. Remais
The Lancet Regional Health - Americas (2021) Vol. 5, pp. 100133-100133
Open Access | Times Cited: 21
Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021–2022 influenza season
Kristin L. Andrejko, Jennifer F. Myers, John J. Openshaw, et al.
Vaccine (2022) Vol. 41, Iss. 6, pp. 1190-1197
Open Access | Times Cited: 14
COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January–30 June 2021)
Sarah M. Hatcher, Stacy Endres‐Dighe, Frederick J. Angulo, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 393-393
Open Access | Times Cited: 12
Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
Jacques Pépin, Annie‐Claude Labbé, Alex Carignan, et al.
Vaccine (2021) Vol. 39, Iss. 50, pp. 7300-7307
Open Access | Times Cited: 15
Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries
John D Clemens, Asma Binte Aziz, Birkneh Tilahun Tadesse, et al.
EClinicalMedicine (2021) Vol. 43, pp. 101253-101253
Open Access | Times Cited: 15
Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations
Jennifer R. Head, Kristin L. Andrejko, Justin V. Remais
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 13
Low risk of SARS-CoV-2 transmission via fomite, even in cold-chain
Julia S. Sobolik, Elizabeth T. Sajewski, Lee‐Ann Jaykus, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top